Dr. Lal PathLabs Board Approves FY26 Results, ₹4 Dividend, Acquisition, New WOS

Dr. Lal PathLabs' Board of Directors approved the audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026. The board recommended a final dividend of ₹4 per equity share for FY26, with June 26, 2026, as the record date. Key strategic moves include the acquisition of a 100% stake in Shahbazkers Diagnostic Centre Private Limited, making it a wholly-owned subsidiary, and the incorporation of a new wholly-owned subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE, for international expansion. Additionally, the board re-appointed (Hony) Brig. Dr. Arvind Lal as Executive Chairman and Mr. Rajit Mehta as an Independent Director. Dr. Reena Nakra and Dr. Saloni Khera were designated as Senior Management Personnel. The re-appointment of M/s Ernst & Young LLP as Internal Auditors and M/s A.G. Agarwal & Associates as Cost Auditors for FY27 was also approved. Finally, 82,750 equity shares were allotted under the Employee Stock Option Plan 2022.